Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2023 | Medical writing bias in myeloma clinical research

James Berenson • 11 Dec 2023
ASH 2023
Multiple Myeloma

James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, speaks on a study examining medical write-ups of multiple myeloma (MM) clinical trials conducted since 2000. The analysis revealed a significant rise in papers authored by individuals employed by drug companies, reaching nearly 50% in 2023, indicating a potential bias in the literature. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Funding: Incyte Corporation

More from James Berenson

The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma 1:16
The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma
James Berenson • 14 Dec 2023
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone 2:07
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
James Berenson • 11 Dec 2023
Outcomes of patients with triple-class refractory myeloma: a single-center retrospective study 1:08
Outcomes of patients with triple-class refractory myeloma: a single-center retrospective study
James Berenson • 11 Dec 2023
Mechanism of action of belantamab mafodotin 1:04
Mechanism of action of belantamab mafodotin
James Berenson • 12 Oct 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals